Left ventricular hypertrophy as a predictor of cardiovascular risk

Journal of Hypertension, Supplement

Volumn 23, Issue 1, 2005, Pages

  Gosse, Philippe ^a  

^a HÔPITAL SAINT ANDRÉ   (France)

Author keywords

Ambulatory blood pressure; Angiotensin II; Angiotensin II receptor blockers; Cardiovascular risk; Left ventricular hypertrophy; Telmisartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; NIFEDIPINE; TELMISARTAN; ANGIOTENSIN II; ATENOLOL; CANDESARTAN; HYDRALAZINE; MINOXIDIL;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; STROKE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; DISEASE MARKER; HYPERTENSION; META ANALYSIS; MORTALITY; PATHOLOGY; PREVALENCE; REMISSION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 18444381423     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000165625.79933.9a     Document Type: Conference Paper

References (53)

1. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
4. Reichek N, Devereux RB. Left ventricular hypertrophy: relationship of anatomic and electrocardiographs findings. Circulation 1981; 63: 1391-1398.
5. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108:7-13.
6. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7:639-650.
7. Liebson PR, Grandits GA, Prineas R, Dianzumba S, Flack JM, Cutler JA, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment Of Mild Hypertension Study (TOMHS). Circulation 1993; 87:476-486.
8. Gosse P, Jullien V, Jarnier P, Lemetayer P, Clementy J. Echocardiographic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of text ventricular mass? J Hum Hypertens 1999; 13:505-509.
9. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829-1835.
10. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104:2039-2044.
11. Gardin JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001; 87:1051-1057.
12. Cipriano C, Gosse P, Bemurat L, Mas D, Lemetayer P, N'tela G, et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14:524-529.
13. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
14. Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study, formulation of a height- and sex-specific classification and its prospective validation. Circulation 1997; 96:1863-1873.
15. Rowlands DB, Ireland MA, Glover DR, McLeay RA, Stallard TJ, Littler WA. The relationship between ambulatory blood pressure and echocardiographically assessed left ventricular hypertrophy. Clin Sci (Lond) 1981; 61(suppl 7):101S-103S.
16. Devereux RB, Pickering TG, Harshfield GA, Kleinert HD, Denby L, Clark L, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regulatory recurring stress. Circulation 1983; 68:470-476:
17. White WB, Dey HM, Schulman P. Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J 1989; 118:782-795.
18. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81:528-536.
19. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
20. Gosse P, Ansoborlo P, Jullien V, Lemetayer P, Clementy J. Ambulatory blood pressure and left ventricular hypertrophy. Blood Press Monit 1997; 2:70-74.
21. Millar-Craig MW, Bishop CN, Raftery EB. Orcadian variation of blood-pressure. Lancet 1978; i:795-797.
22. Cuspidi C, Macca G, Sampieri L, Fusi V, Severgnini B, Michev I, et al. Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients. J Hypertens 2001; 19:1539-1545.
23. Cuspidi C, Meani S, Salerno M, Valerio C, Fusi V, Severgnini B, et al. Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure. J Hypertens 2004; 22:273-280.
24. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Circadian variation in the frequency of onset of acute myocardial infraction. N Engl J Med 1985; 313:1315-1322.
25. Marler JR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, et al. Morning increase in onset of ischemic stroke. Stroke 1989; 20:473-476.
26. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
27. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997; 2:47-51.
28. Kuwajima I, Mitani K, Miyao M, Suzuki Y, Kuramoto K, Ozawa T. Cardiac implications of the morning surge in blood pressure in elderly hypertensive patients: relation to arising time. Am J Hypertens 1995; 8:29-33.
29. Gosse P, Ansoborlo P, Lemetayer P, Clementy J. Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. Am J Hypertens 1997; 10:505-510.
30. Gosse P, Lasserre R, Minifie C, Lemetayer P, Clementry J. Blood pressure surge on rising. J Hypertens 2004; 22:1113-1118.
31. de Simone G, Verdecchia P, Pede S, Gorini M, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. Hypertension 2002; 40:470-476.
32. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 2002; 105:85-92.
33. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
34. Ciulla MM, Paliotti R, Esposito A, Diez J, Lopez B, Dahlöf B, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004; 110:552-557.
35. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6:85-90.
36. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
37. Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
38. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998; 13:564-569.
39. Liebson PR. Left ventricular hypertrophy. Curr Treat Options Cardiovasc Med 1999; 1:219-230.
40. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
41. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J Hypertens 2000; 18:1465-1475.
42. Galzerano D, Del Viscovo L, Tammaro P, Breglio R, Cercielo A, Lamma D, et al. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared to carvedilol on left ventricular mass: a multicenter randomized study. 53rd Annual Scientific Session of the American College of Cardiology; 7-10 March 2004; New Orleans, USA. New York: Elsevier; 2004.
43. Gosse P, Dubourg O, Gueret P. Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 2003; 21:217-221.
44. Gosse P, de Simone G, Dubourg O, Gueret P, Schmieder R. Serial echocardiographic assessment of left ventricular mass: how blinded should readers be? J Hypertens 2004; 22:1813-1818.
45. Devereux RB, Dahlöf B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110:1456-1462.
46. Dahlöf B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20:1855-1864.
47. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20:2293-2300.
48. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104:1248-1254.
49. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabati-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
50. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
51. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15:1021-1028.
52. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
53. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899.